Please use this identifier to cite or link to this item:
|Title:||Cytotoxicity of 213Bi- and 225Ac-Immunoconjugates|
|Authors:||KASPERSEN F.m.; BOS E.; DOORNMALEN A.v.; APOSTOLIDIS Christos|
|Citation:||Nuclear Medicine Communications vol. 16 p. 468-476|
|Type:||Articles in periodicals and books|
|Abstract:||The paper describes in vitro cytotoxicity experiments with 213-Bi- and 225-Ac-immunoconjugates on the human epidermoid tumour cell line A431 using a blood group A-reactive murine IgG (2D11) as the specific antibody and MOPC 21 as the control antibody. With both radionuclides, specific cell-killing was achieved. The observed cytotoxicity of 213-Bi (T 1/2 = 47 min) indicates that this radionuclide is a useful alternative for the alpha-emitter 212-Bi in the treatment of blood-borne malignancies. 225-Ac-immuno-conjugates may be applicable for the treatment of solid tumours, since the daughter radionuclides of 225-Ca contribute to the cytotoxic efficacy by a field effect (i.e. toxicity in an area distal from antibody-binding site). The lack of an adequate chelator for 225-Ac is a major drawback.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.